Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icovamenib Food Effect and Formulation Study in Healthy Volunteers
NCT07254286Phase 1Completed
- Sponsor
- Biomea Fusion
- Start
- Sep 2025
- Primary completion
- Jan 2026
- Modality
- Covalent Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of icovamenib in type 2 diabetes mellitus (T2DM), sponsored by Biomea Fusion. Primary endpoint: Pharmacokinetic Profile at 2 weeks. Started Sep 2025; status: completed.
02
Drugs
icovamenib
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07254286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07254286.